The Markets for Image-Guided Surgery: Location, Location...and Guidance

The market for image-guided surgical systems is worth $1.2 billion in 2005, according to a report recently issued by Medtech Insight, $1 billion attributable to interventional imaging, and $155.2 million to the sales of surgical navigation systems. The market is expected to experience a compound annual growth rate of 5.5% for the next several years, a slightly higher rate than the 4.1% forecast for the imaging industry as a whole.

The promise of image-guided surgery (IGS), according to "US Markets for Image-Guided Surgery Products," a report just out from Windhover Information's Medtech Insight division, has always been to improve the clinical utility and cost-effectiveness of chosen treatment protocols. The report defines the segment as any technologies that enable the intraoperative use of a representation of patient anatomy, obtained via either direct imaging techniques or computerized methods. Imaged-guided surgery has the potential to improve long-term patient outcomes, minimize surgical trauma, and reduce hospital-length-of stay, because precise targeting results in better removal of diseased tissues and minimal damage to adjacent tissue structures. For example, in arthroplasty procedures of the joint--a rapidly growing segment of the orthopedics industry--image guidance enables smaller tissue-destroying access incisions.

Overall, image-guided surgical systems have been slow to make inroads into the market. In a health care environment of cost containment, IGS products face adoption hurdles as expensive, adjunctive technologies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.